

Accepted Manuscript


Evidence and Perspectives on the 24-hour Management of Hypertension: Hemodynamic Biomarker-Initiated 'Anticipation Medicine' for Zero Cardiovascular Event

Kazuomi Kario

PII: S0033-0620(16)30027-5
DOI: doi: [10.1016/j.pcad.2016.04.001](https://doi.org/10.1016/j.pcad.2016.04.001)
Reference: YPCAD 726

To appear in: *Progress in Cardiovascular Diseases*

Received date: 8 April 2016
Accepted date: 8 April 2016



Please cite this article as: Kario Kazuomi, Evidence and Perspectives on the 24-hour Management of Hypertension: Hemodynamic Biomarker-Initiated 'Anticipation Medicine' for Zero Cardiovascular Event, *Progress in Cardiovascular Diseases* (2016), doi: [10.1016/j.pcad.2016.04.001](https://doi.org/10.1016/j.pcad.2016.04.001)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Evidence and Perspectives on the 24-hour Management of Hypertension: Hemodynamic Biomarker-Initiated ‘Anticipation Medicine’ for Zero Cardiovascular Event

¹⁻³ Kazuomi Kario, MD, PhD, FACP, FACC, FAHA, FESC

¹Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan

²Jichi Medical University Center of Excellence, Cardiovascular Research and Development (JCARD), Tochigi, Japan

³Hypertension Cardiovascular Outcome Prevention and Evidence in Asia (HOPE Asia) Network, Tokyo, Japan.

Disclosures and Conflict of Interest:

Dr Kario has received research grant from Teijin Pharma Limited, Novartis Pharma K.K., Takeda Pharmaceutical Co., Ltd., Omron Healthcare Co., Ltd., Fukuda Denshi and honoraria from Mochida Pharmaceutical Co., LTD, Takeda Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., and Sumitomo Dainippon Pharma Co., Ltd..

Correspondence to: Professor Kazuomi Kario, Chairman, Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, 3311-1, Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.

Tel: +81-285-58-7538; Fax: +81-285-44-4311; E-mail: kkario@jichi.ac.jp

Download English Version:

<https://daneshyari.com/en/article/5619542>

Download Persian Version:

<https://daneshyari.com/article/5619542>

[Daneshyari.com](https://daneshyari.com)